Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX vs mFOLFOX 6 in High Risk Stage III Colon Cancer
NCT05179889Phase 3Recruiting
- Sponsor
- Chungnam National University Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2028
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer, sponsored by Chungnam National University Hospital. Started Jul 2021; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05179889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179889.